News Related to IKZF1/3 Degrader

Related coverage linked through entity extraction aliases.

C4 Therapeutics Doses First Patient in Phase 2 Myeloma Trial, Targets 2028 NDA Submission

Mar 08, 2026

C4 Therapeutics has initiated its Phase 2 MOMENTUM trial of cemsidomide in relapsed/refractory multiple myeloma, targeting enrollment completion in Q1 2027 and a registrational dataset by 2028. The company plans a combination study with elranatamab in Q2 2026.

Cytokinetics Launches MYQORZO; C4 Therapeutics Advances Cemsidomide Trial

Feb 25, 2026

Cytokinetics launches MYQORZO for obstructive hypertrophic cardiomyopathy following FDA approval, while C4 Therapeutics doses first patient in Phase 2 trial of cemsidomide for relapsed/refractory multiple myeloma.